One Less Option For Breast Cancer Treatment

December 18, 2010 09:55

Nanny state-ism has reached new, dangerous heights. For women with breast cancer, decisions about treatment have been taken out of their hands a little more, and placed under purview of the FDA.

Helen Whalen Cohen at


The agency announced that it would no longer recommend that the drug Avastin be used to treat breast cancer, saying that it is too expensive, has potential bad side effects and isn’t as effective as originally believed. Doctors will still be able to prescribe Avastin, but insurers are less likely to pay for it (much to the chagrin of patient advocacy groups). Welcome to the beginning of Obamacare, in which your medical choices will be influenced by bureaucratic decision making.


Help Make A Difference By Sharing These Articles On Facebook, Twitter And Elsewhere: